Key result
Tumor LPL and CD36 expression fuels cancer growth across common malignancies by driving lipolytic fatty acid uptake.
Why the study?
Do solid tumor cells express lipoprotein lipase (LPL) and CD36 to acquire exogenous dietary fatty acids from circulating lipoproteins to fuel proliferation and resist fatty acid synthesis inhibition?
Do solid tumor cells express lipoprotein lipase (LPL) and CD36 to acquire exogenous dietary fatty acids from circulating lipoproteins to fuel proliferation and resist fatty acid synthesis inhibition?
Solid tumors universally express lipoprotein lipase and frequently express CD36 to acquire exogenous circulating fatty acids, indicating that targeting de novo fatty acid synthesis alone may fail without also inhibiting lipolysis or dietary fat uptake.
Answers are grounded in this paper and cite their sources.
De novo fatty acid synthesis inhibition alone may be insufficient; leaves open combined lipolysis or CD36 targeting in solid tumors.
Many types of cancer cells require a supply of fatty acids (FA) for growth and survival, and interrupting de novo FA synthesis in model systems causes potent anticancer effects. We hypothesized that, in addition to synthesis, cancer cells may obtain preformed, diet-derived FA by uptake from the bloodstream. This would require hydrolytic release of FA from triglyceride in circulating lipoprotein particles by the secreted enzyme lipoprotein lipase (LPL), and the expression of CD36, the channel for cellular FA uptake. We find that selected breast cancer and sarcoma cells express and secrete active LPL, and all express CD36. We further show that LPL, in the presence of triglyceride-rich lipoproteins, accelerates the growth of these cells. Providing LPL to prostate cancer cells, which express low levels of the enzyme, did not augment growth, but did prevent the cytotoxic effect of FA synthesis inhibition. Moreover, LPL knockdown inhibited HeLa cell growth. In contrast to the cell lines, immunohistochemical analysis confirmed the presence of LPL and CD36 in the majority of breast, liposarcoma, and prostate tumor tissues examined (n = 181). These findings suggest that, in addition to de novo lipogenesis, cancer cells can use LPL and CD36 to acquire FA from the circulation by lipolysis, and this can fuel their growth. Interfering with dietary fat intake, lipolysis, and/or FA uptake will be necessary to target the requirement of cancer cells for FA.
No takes yet. Share an insight, caveat, or question.
Kuemmerle et al. (2011) studied Solid tumors (breast cancer, liposarcoma, and prostate cancer) (n=181). Lipoprotein lipase (LPL) and CD36 expression / exogenous LPL provision or siRNA knockdown vs. Control media, lipoprotein-deficient serum, or control luciferase siRNA was evaluated on Immunohistochemical expression of LPL and CD36 in human tumor tissues and tumor cell proliferation in culture. Lipoprotein lipase (LPL) and CD36 were universally or predominantly expressed across 181 human breast, liposarcoma, and prostate tumor tissues, enabling lipolytic fatty acid acquisition to fuel growth.
Synapse has enriched 10 related papers. Consider them for comparative context: